VCEL - Vericel Corporation
| Previous Close | 13.23 |
| Open | 13.21 |
| Bid | 12.70 x 800 |
| Ask | 12.69 x 1000 |
| Day's Range | 12.32 - 13.21 |
| 52 Week Range | 3.30 - 15.29 |
| Volume | 423,376 |
| Avg. Volume | 919,134 |
| Market Cap | 540.918M |
| Beta (3Y Monthly) | 4.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.62 |
- Simply Wall St.•10 days ago
Should You Worry About The Vericel Corporation’s (NASDAQ:VCEL) Shareholder Register?
Every investor in Vericel Corporation (NASDAQ:VCEL) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
- Zacks•11 days ago
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
- Zacks•12 days ago
How to Invest in the Hot Medical Device Innovators
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
- ACCESSWIRE•17 days ago
Stem Cell Companies Moving The Markets
HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently ...
Market Realist•18 days agoAnalysts Are Bullish on Vericel Stock in September
Vericel (VCEL) is a biopharmaceutical company focused on the use of cell therapies to target the underserved opportunity in the burn care and sports medicines markets. The FDA noted that in December 2016, the company secured FDA approval for MACI, a cartilage repair product, to treat symptomatic and full-thickness cartilage defects of the knees. According to Vericel’s September investor presentation, Epicel is used for permanent skin replacement in patients suffering from severe burns.
- Bloomberg•23 days ago
This Implant Helps Heal Knees With a Patient’s Own Cartilage
At first, Courtney Mannino blamed the dull ache in her left knee on a ligament she’d torn in high school. The diagnosis was unlucky: cartilage damage too severe to be treated with cortisone shots and over-the-counter painkillers, yet not severe enough to justify the kind of knee replacement surgery reserved for patients with advanced arthritis and way more years behind them than Mannino’s 29. With few choices, the Cedars-Sinai pediatrician decided to try a first-of-its-kind treatment from biotech company Vericel Corp., which specializes in tissue engineering.
- GlobeNewswire•24 days ago
Vericel to Present at Multiple Upcoming Conferences
CAMBRIDGE, Mass., Sept. 21, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry ...
- ACCESSWIRE•26 days ago
Stem Cell Deals Moving the Markets
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / The stem cell market has been very active recently, several stocks have been making deals and major breakthroughs. One stem cell play the market seems ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of VCEL earnings conference call or presentation 6-Aug-18 8:30pm GMT
Q2 2018 Vericel Corp Earnings Call
- GlobeNewswire•2 months ago
Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
CAMBRIDGE, Mass., Aug. 06, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights ...
- ACCESSWIRE•2 months ago
Vericel Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Vericel Corporation (NASDAQ: VCEL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. ...
- Benzinga•2 months ago
Vericel's Earnings Preview
Vericel (NASDAQ: VCEL ) announces its next round of earnings this Monday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Analysts are expecting ...
- GlobeNewswire•3 months ago
Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
CAMBRIDGE, Mass., July 26, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, ...
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...
- GlobeNewswire•3 months ago
Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass., July 23, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call ...
- ACCESSWIRE•3 months ago
3 Biotech Stocks to Bet on in the Second Half of 2018
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential. HENDERSON, NV / ACCESSWIRE ...
- Simply Wall St.•4 months ago
When Will Vericel Corporation (NASDAQ:VCEL) Turn A Profit?
Vericel Corporation’s (NASDAQ:VCEL): Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. With the latestRead More...
- ACCESSWIRE•4 months ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of VCEL earnings conference call or presentation 8-May-18 12:30pm GMT
Q1 2018 Vericel Corp Earnings Call
- Yahoo Finance•5 months ago
What this year's top fund managers are doing to smoke the competition
As big names have treaded water, the best performing funds have feasted in market famine thanks to little-known healthcare and technology companies.
